Gujarat Magazine

Graves’ Ophthalmopathy Market and Epidemiology 2032: Clinical Trial, Pipeline, FDA Approval, Companies | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron, ValenzaBio

 Breaking News
  • No posts were found

Graves’ Ophthalmopathy Market and Epidemiology 2032: Clinical Trial, Pipeline, FDA Approval, Companies | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron, ValenzaBio

March 11
16:46 2024
Graves' Ophthalmopathy Market and Epidemiology 2032: Clinical Trial, Pipeline, FDA Approval, Companies | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron, ValenzaBio
Graves’ Ophthalmopathy Market

DelveInsight’s “Graves’ Ophthalmopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graves’ Ophthalmopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).


To know more about the Graves’ Ophthalmopathy market report offerings, click here: Graves’ Ophthalmopathy market forecast


Graves’ Ophthalmopathy Market Key Facts

  • The total Graves’ Ophthalmopathy market size in the 7MM was approximately USD 1,993 million in 2022.
  • Among EU4 countries, Germany accounted for the maximum Graves’ Ophthalmopathy market size in 2022.
  • There are several promising Graves’ Ophthalmopathy drugs in the pipeline, including VRDN-001 (Viridian Therapeutics) and IMVT-1401 (Immunovant Sciences GmbH), among others, expected to hit the market in the near future.
  • The total prevalent cases of Graves Ophthalmopathy in the United States were around 1,012,000 cases in 2022.
  • In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from Graves’ Ophthalmopathy. 
  • Teprotumumab (Tepezza): Teprotumumab, an FDA-approved treatment for thyroid eye disease, has shown promising results. In a phase 2 trial, it was found to reduce eye protrusion by more than two millimeters in over 70% of patients. Subsequently, a phase 3 trial (OPTIC) further validated its safety and efficacy.
  • Atorvastatin and IvGCs Combination: A recent phase 2 randomized clinical trial explored the combination of atorvastatin (a statin) and intravenous glucocorticoids (ivGCs) for moderate-to-severe active Graves’ Ophthalmopathy. Although initial results were positive, a longer phase 3 trial is needed to establish its effectiveness.


Graves’ Ophthalmopathy Overview

Graves’ ophthalmopathy is a complex orbital inflammatory disease that can be sight-threatening, debilitating, and disfiguring. Graves’ ophthalmopathy, also known as thyroid eye disease (TED), is named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goitre, rapid heartbeat, and exophthalmos. 

Graves’ ophthalmopathy affects eye muscles, eyelids, tear glands, and fatty tissues behind the eye to become inflamed. This can cause the eyes and eyelids to become red, swollen, and uncomfortable, and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes). Untreated thyroid dysfunction (hyper- or hypothyroidism) is associated with the development and progression of Graves’ ophthalmopathy. Smoking is the strongest risk factor associated with Graves’ ophthalmopathy.

According to NORD, the exact prevalence (i.e., the number of people who have a disorder in a specific population at a specific time) of Graves’ ophthalmopathy is not known but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population.


Request for a free sample report @


Graves’ Ophthalmopathy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Graves’ Ophthalmopathy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Graves’ Ophthalmopathy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.


Graves’ Ophthalmopathy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Graves’ Ophthalmopathy Epidemiology, Segmented as –

  • Total Prevalent cases of Graves’ ophthalmopathy in 7MM [2019–2032
  • Gender-specific cases of Graves’ ophthalmopathy in 7MM [2019–2032]
  • Severity-Specific Cases of Graves’ ophthalmopathy in 7MM [2019–2032]
  • Age-specific cases of Graves’ ophthalmopathy in 7MM [2019–2032]


Request for a free sample report @


Graves’ Ophthalmopathy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Graves’ Ophthalmopathy market or expected to be launched during the study period. The analysis covers the Graves’ Ophthalmopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graves’ Ophthalmopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Learn How the Graves’ Ophthalmopathy Market Will Evolve and Grow by 2032 @


Graves’ Ophthalmopathy Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Graves Ophthalmopathy. Currently, Novartis is leading the therapeutics market with its Graves Ophthalmopathy drug candidates in the most advanced stage of clinical development.


Leading Companies in the Graves Ophthalmopathy Therapeutics Market Include:

  • Novartis
  • Harbour BioMed
  • Viridian Therapeutics, Inc.
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.
  • Sling Therapeutics, Inc.
  • ValenzaBio
  • Argenx
  • HanAll Biopharma
  • Immunovant Sciences
  • Novartis
  • Viridian Therapeutics
  • And Many Others


Graves Ophthalmopathy Therapies Covered in the Report Include:

  • Tepezza (teprotumumab) : Horizon Therapeutics
  • Secukinumab: Novartis
  • Batoclimab (HBM9161): Harbour BioMed
  • TEPEZZA (teprotumumab): Horizon Therapeutics
  • Batoclimab: Immunovant Sciences
  • VRDN-001: Viridian Therapeutics
  • Linsitinib : Sling Therapeutics
  • And Many More


The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

  1. Key Insights
  2. Executive Summary 
  3. Graves’ Ophthalmopathy Competitive Intelligence Analysis
  4. Graves’ Ophthalmopathy Market Overview at a Glance
  5. Graves’ Ophthalmopathy Disease Background and Overview
  6. Graves’ Ophthalmopathy Patient Journey
  7. Graves’ Ophthalmopathy Epidemiology and Patient Population (In the US, EU5, and Japan)
  8. Graves’ Ophthalmopathy Treatment Algorithm, Current Treatment, and Medical Practices
  9. Graves’ Ophthalmopathy Unmet Needs
  10. Key Endpoints of Graves’ Ophthalmopathy Treatment
  11. Graves’ Ophthalmopathy Marketed Products
  12. Graves’ Ophthalmopathy Emerging Drugs and Latest Therapeutic Advances
  13. Graves’ Ophthalmopathy Seven Major Market Analysis
  14. Attribute Analysis
  15. Graves’ Ophthalmopathy Market Outlook (In US, EU5, and Japan)
  16. Graves’ Ophthalmopathy Access and Reimbursement Overview
  17. KOL Views on the Graves’ Ophthalmopathy Market
  18. Graves’ Ophthalmopathy Market Drivers
  19. Graves’ Ophthalmopathy Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States